Hikma制药公司取代CEO Riad Mishlawi和Said Darwazah, 由于利润下降和贸易担忧, Hikma Pharmaceuticals replaced CEO Riad Mishlawi with Said Darwazah amid a 25% share drop since January due to declining profits and trade worries.

Hikma制药公司取代了CEO Riad Mishlawi, 代之以前CEO Said Darwazah, 其股价自1月以来因利润下降和贸易不确定因素下跌25%后立即生效。 Hikma Pharmaceuticals has replaced CEO Riad Mishlawi with former CEO Said Darwazah, effective immediately, after its share price fell 25% since January due to declining profits and trade uncertainties. 米什拉维经双方协议下台,将退休。 Mishlawi stepped down by mutual agreement and will retire. 该公司的财务指导没有改变,新的英国-美国贸易协议取消了联合王国对美国药品出口的关税,以换取国民保健体系增加药品支出,缓解了对美国潜在贸易壁垒和经营的担忧。 The company’s financial guidance remains unchanged, and a new UK-US trade deal eliminates tariffs on UK pharmaceutical exports to the US in exchange for increased NHS spending on medicines, easing concerns over potential US trade barriers and operations.